Paper Details

  1. Home
  2. Paper Details

Network meta-analysis of glucose-lowering drug treatment regimens with the potential risk of hypoglycemia in patients with type 2 diabetes mellitus in terms of glycemic control and severe hypoglycemia.

Author: FujiharaKazuya, IshiguroHajime, IwanagaMidori, KatoKiminori, KitazawaMasaru, KodamaSatoru, MatsubayashiYasuhiro, NakagawaYoshimi, ShimanoHitoshi, SoneHirohito, TanakaShiro, YamadaTakaho

Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This network meta-analysis aims to determine the optimal glucose-lowering drug treatment regimens for type 2 diabetes (T2D) patients in terms of glycemic control and severe hypoglycemia risk. The study finds that combining insulins with non-insulin glucose-lowering agents, excluding sulfonylurea or glinide, can improve glycemic control compared to insulins alone. The study also suggests that glinide plus thiazolidinedione and premixed insulin plus glucagon-like peptide-1 receptor agonist are promising combinations for achieving good glycemic control while minimizing the risk of severe hypoglycemia.
Paper Details　
Original Abstract of the Article :
Insulin and its secretagogues are essential for some patients with type 2 diabetes (T2D) to maintain good glycemic control (GC), but severe hypoglycemia (SH) is a concern. This network meta-analysis aimed to find optimal glucose-lowering drug treatment regimens in terms of GC and SH in T2D patients....See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1177/10815589221149188

データ提供：米国国立医学図書館（NLM）

Optimizing Glucose-Lowering Therapy in Type 2 Diabetes: A Navigational Guide Through the Desert of Treatment Options

Type 2 diabetes is a complex condition requiring careful management of blood glucose levels. This network meta-analysis explores the optimal glucose-lowering drug treatment regimens for patients with type 2 diabetes, considering both glycemic control and the risk of severe hypoglycemia. The authors analyzed data from 137 eligible trials comparing various treatment combinations involving insulin and non-insulin glucose-lowering agents.

A Balanced Approach: Navigating the Risks and Rewards of Diabetes Treatment

The analysis revealed that combining non-insulin glucose-lowering agents with insulin therapies can improve glycemic control while minimizing the risk of severe hypoglycemia. The authors identified specific combinations, such as premixed insulin plus glucagon-like peptide-1 receptor agonist (Mix-ins + GLP1) and glinide plus thiazolidinedione (glinide + TZD), as potentially beneficial in achieving optimal glycemic control while mitigating the risk of hypoglycemia.

A Beacon of Hope for Diabetes Management

This network meta-analysis provides valuable insights for clinicians managing type 2 diabetes. The study highlights the importance of personalized treatment strategies tailored to individual patient needs and risk profiles. By considering both glycemic control and the risk of hypoglycemia, clinicians can optimize treatment regimens and improve patient outcomes.

Dr. Camel's Conclusion

This network meta-analysis provides valuable guidance for managing type 2 diabetes. The study emphasizes the importance of balancing glycemic control with the risk of severe hypoglycemia. By considering a combination of non-insulin glucose-lowering agents and insulin therapies, clinicians can optimize treatment regimens and improve patient outcomes.

Date :
  1. Date Completed 2023-03-21
  2. Date Revised 2023-04-06
Further Info :

Pubmed ID

36695427

DOI: Digital Object Identifier

10.1177/10815589221149188

Related Literature

Article Analysis
・Effective treatment of health checkup
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.